睿知中国医院研究地图
候选清单

即将招募淋巴瘤III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由上海交通大学医学院附属瑞金医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方上海交通大学医学院附属瑞金医院Ruijin Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07511114,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. 1. Have previously received systemic or local treatments, including chemotherapy;

    排除标准第 1 条

    2. Have previously undergone autologous stem cell transplantation;

    排除标准第 2 条

    12. Patients with positive HBsAg test results must undergo HBV DNA testing and can only be enrolled after becoming negative. Additionally, if the HBsAg test result is negative but the HBcAb test result is positive (regardless of the HBsAb status), HBV DNA testing is also required. If the result is positive, treatment must be administered until becoming negative before enrollment;

    排除标准第 12 条

  3. 4. ECOG performance status score of 0, 1, or 2;

    入选标准第 4 条

  4. 7. Laboratory test values during screening: (unless caused by lymphoma); A. Neutrophil count <1.5*10\^9/L; B. Platelet count < 75 x 10\^9/L; C. ALT or AST is 2 times higher than the upper limit of normal, and AKP and bilirubin are 1.5 times higher than the upper limit of normal; D. Creatinine level is higher than 1.5 times the upper limit of normal;

    排除标准第 7 条

  5. 3. Previously had a history of other malignant tumors, excluding basal cell carcinoma and cervical carcinoma in situ;

    排除标准第 3 条

    11. Individuals infected with HIV.

    排除标准第 11 条

  6. 10. Pregnant or lactating women;

    排除标准第 10 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07511114,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. 1. Histopathological diagnosis confirmed as diffuse large B-cell lymphoma, with CD20 positivity;
  2. 2. Simultaneous expression of MYC and BCL2, according to the WHO standard for immunohistochemistry: MYC ≥ 40%, BCL2 ≥ 50%
  3. 3. Age ≥ 18 years old and ≤ 75 years old;
  4. 4. ECOG performance status score of 0, 1, or 2;
  5. 5. International Prognostic Index (IPI) > 1
  6. 6. No history of malignant tumor; no concurrent occurrence of other tumors;
  7. 7. Patients with an expected lifespan of at least 6 months, as determined by the researcher;
  8. 8. The patient or their legal representative must provide written informed consent before undergoing any special examinations or procedures in the study.

排除标准:Exclusion Criteria:

  1. 1. Have previously received systemic or local treatments, including chemotherapy;
  2. 2. Have previously undergone autologous stem cell transplantation;
  3. 3. Previously had a history of other malignant tumors, excluding basal cell carcinoma and cervical carcinoma in situ;
  4. 4. Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, severe infectious diseases, etc;
  5. 5. Primary central nervous system lymphoma;
  6. 6. Left ventricular ejection fraction (LVEF) is less than or equal to 50%;
  7. 7. Laboratory test values during screening: (unless caused by lymphoma); A. Neutrophil count <1.5*10\^9/L; B. Platelet count < 75 x 10\^9/L; C. ALT or AST is 2 times higher than the upper limit of normal, and AKP and bilirubin are 1.5 times higher than the upper limit of normal; D. Creatinine level is higher than 1.5 times the upper limit of normal;
  8. 8. Other concurrent and uncontrolled medical conditions that the researcher believes will affect the patient's participation in the study.
  9. 9. Patients with mental illness or other patients known or suspected to be unable to fully comply with the study protocol;
  10. 10. Pregnant or lactating women;
  11. 11. Individuals infected with HIV.
  12. 12. Patients with positive HBsAg test results must undergo HBV DNA testing and can only be enrolled after becoming negative. Additionally, if the HBsAg test result is negative but the HBcAb test result is positive (regardless of the HBsAb status), HBV DNA testing is also required. If the result is positive, treatment must be administered until becoming negative before enrollment;

引自 ClinicalTrials.gov, NCT07511114, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07511114,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07511114